Dr. Sophia Frentzas MBBS, BSc (Hons 1), MRCP (Lon UK), PhD, MRCP (MedOnc UK) PGDip (Oncology), FRACP
Dr Sophia Frentzas is a medical oncologist and clinical researcher who graduated from Imperial College School of Medicine, in London, in 2002, before completing her medical training with the Royal College of Physicians in the United Kingdom in 2006. She undertook an early fellowship in the drug development unit and translational research at the Royal Marsden Hospital and Institute of Cancer Research in Sutton (UK) in 2008 and subsequently completed her specialist training in Medical Oncology at The Royal Marsden Hospital, under the auspices of the Royal College of Physicians and the Association of Cancer Physicians in London (UK) in 2015. During this time, she also completed a laboratory-based, translational PhD as a GI Cancer Research Fellow, at the Institute of Cancer Research, University of London and was awarded her doctorate certificate in 2014.
Since migrating to Australia in 2016, Dr Frentzas has gained fellowship with the Royal Australasian College of Physicians and has worked as a Full Time Specialist in Medical Oncology at the Alan Walker Cancer Centre, Royal Darwin Hospital, NT. During this time, she chaired the Clinical Trials Unit at the Alan Walker Cancer Centre, was a member of the NT Cancer Care Network, was involved in outreach oncology clinic support in the Northern Territory, the conduct of Cultural Awareness and Safety, and in The Flinders University medical student teaching program.
Dr Frentzas is now part of the medical oncology team at Monash Health where she specialises in the treatment of patients with colorectal, upper gastrointestinal tract, breast, and gynaecological tract cancers. She is also responsible for the development and conduct of early and late clinical trials, and also has input into the translational aspect of cancer research.
Her main research interests are focused on novel and personal approaches for the treatment of solid tumours, particularly in targeting aberrant pathways for angiogenesis, and on the investigation of strategies to overcome resistance to conventionally employed therapeutic agents. Her research has been published in a number of peer-reviewed, high impact factor journals, and abstracts. She has also had the opportunity to present her work at several national and international conferences.
Dr Frentzas is an active member of the European Society of Medical Oncology (ESMO), American Society of Clinical Oncology (ASCO), American Association for Cancer Research (AACR), and Medical Oncology Group of Australia (MOGA).